This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ArmaGen Technologies, Inc. Hires Biotech Executive As CEO

LOS ANGELES, Jan. 3, 2013 /PRNewswire/ -- ArmaGen Technologies, Inc., a leader in the delivery of biotherapeutics targeting the central nervous system (CNS), today announced James Callaway, Ph.D. as Chief Executive Office and member of the Board of Directors.  Dr. Callaway was most recently President and CEO of Cebix Inc. and joins ArmaGen with nearly 30 year of experience in biotechnology research and development, including executive leadership positions at Bayer and Elan Pharmaceuticals prior to joining Cebix.

"We are delighted to welcome Dr. Callaway, a respected drug developer and biotech executive, as CEO of ArmaGen. His extensive experience working within the realm of CNS disorders at both small biotech companies and major pharmaceutical firms will be invaluable to ArmaGen as the company develops its product pipeline and platform technology," said William M. Pardridge, MD, Founder and Chief Scientific Officer of ArmaGen. " I am confident that under his leadership, the dedicated staff at ArmaGen will be well positioned to deliver compelling clinical data for our therapeutic candidates."

" I am honored to lead ArmaGen through this period of clinical experimentation and validation. The potential for this proprietary Trojan horse technology to transform the therapeutic options in the area of CNS therapies is very exciting," said Dr. Callaway. " In addition, the specific focus on orphan drug indications within the CNS creates a very attractive development pathway through which to validate this platform technology."

Dr. Callaway will join Dr. Pardridge on the ArmaGen Board of Directors along with Stuart Swiedler, MD, PhD, Martin Heidecker PhD (Boehringer Ingelheim Venture Fund), and Arthur Tzianabos, PhD (Shire plc).

Prior to joining ArmaGen, Dr. Callaway served as President and CEO of Cebix Inc., a biology driven company focused on reducing the sequelae associated with diabetic peripheral neuropathy with a peptide therapeutic.  Previously, Dr. Callaway filled several executive roles during his thirteen-year tenure at Elan Pharmaceutical, including program executive for the Alzheimer's Immunotherapy program (encompassing 5 development candidates including bapinuzumab and AN-1792), head of development and head of pharmaceutical development.  During his tenure at Elan he also led the development and approval of MyoBloc ®and the production of Tysabri ®.  Prior to Elan, Dr. Callaway had development responsibilities at Bayer Pharmaceuticals in Berkeley, SmithKline Beecham (GSK) in King of Prussia as well as Ingene in Santa Monica (Xoma).  Dr. Callaway received his Ph.D. in Biological Chemistry from UCLA with a focus on peptide chemistry and has filed and defended numerous NDAs and INDs during the course of his career.

Victoria Sergeant & Associates led the successful executive search for this position.

About ArmaGen® Technologies

The ArmaGen molecular Trojan horse technology has the potential to re-engineer recombinant proteins for BBB penetration for the treatment of diseases of the brain and spinal cord. The long-term mission at ArmaGen is the development of BBB-penetrating biopharmaceuticals for diseases of the CNS that affect over 250 million people world-wide. Initially, the company will focus on orphan diseases of the CNS with lead biopharmaceuticals for Mucopolysaccharidosis (MPS) Type I, or Hurler's syndrome and MPS Type II, or Hunter's disease.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs